Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Harvard Business School
Fish and Richardson
Moodys
Federal Trade Commission
AstraZeneca
Mallinckrodt
US Department of Justice
Cantor Fitzgerald
Colorcon

Generated: January 18, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,370,525

« Back to Dashboard

Summary for Patent: 9,370,525
Title:Modified release preparations containing oxcarbazepine and derivatives thereof
Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
Inventor(s): Bhatt; Padmanabh P. (Rockville, MD), Kidane; Argaw (Montgomery Village, MD), Edwards; Kevin (Lovettsville, VA)
Assignee: Supernus Pharmaceuticals, Inc. (Rockville, MD)
Application Number:14/807,165
Patent Claim Types:
see list of patent claims
Use; Formulation; Compound; Composition; Dosage form;

Drugs Protected by US Patent 9,370,525

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-001 Oct 19, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-002 Oct 19, 2012 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms OXTELLAR XR oxcarbazepine TABLET, EXTENDED RELEASE;ORAL 202810-003 Oct 19, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,370,525

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,617,600 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Subscribe
7,722,898 Modified-release preparations containing oxcarbazepine and derivatives thereof ➤ Subscribe
9,119,792 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Subscribe
7,910,131 Method of treating seizures using modified release formulations of oxcarbazepine ➤ Subscribe
8,821,930 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Subscribe
8,211,464 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Subscribe
8,017,149 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Subscribe
9,119,791 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Subscribe
9,351,975 Modified release preparations containing oxcarbazepine and derivatives thereof ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,370,525

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan 2013079267 ➤ Subscribe
Mexico 2008013675 ➤ Subscribe
European Patent Office 2359830 ➤ Subscribe
European Patent Office 2026815 ➤ Subscribe
Germany 602007012236 ➤ Subscribe
China 101489560 ➤ Subscribe
Spain 2360423 ➤ Subscribe
Spain 2396051 ➤ Subscribe
Japan 2009535351 ➤ Subscribe
Japan 5253381 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Covington
Julphar
AstraZeneca
Cerilliant
Johnson and Johnson
Daiichi Sankyo
Citi
Healthtrust
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot